In Depth 1 Aug 2022 The biggest US biotech investments in July 2022 The asthma specialist Areteia Therapeutics took the U.S.’ top private biotech investment crown in July 2022, with runners-up including liquid biopsy firm Delfi Diagnostics and the metabolic disease drug developer… August 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2018 Oxford Biotech Launches with €26M to Target ‘Immunometabolism’ …growth through targeting metabolic pathways has the potential to deliver new approaches to treat a wide range of severe diseases, particularly in the areas of immuno-oncology and immuno-inflammation.” The… October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Laevoroc Oncology pushes for relapsed leukemia cure …into the immunoregulatory functions of purine nucleoside phosphorylase (PNP) with Laevoroc’s PNP inhibitor, LR 09. The research shows that PNP is a novel metabolic immune checkpoint and LR 09 (Ulodesine),… December 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Epigenic Therapeutics raises $20M for gene editing technology …metabolic, and rare disease models. About Epigenic Therapeutics Epigenic Therapeutics is dedicated to developing next generation gene editing therapy utilizing regulation of the epigenetic genome for a variety of diseases…. August 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 MetrioPharm reveals COVID-19 study data MetrioPharm AG, a Swiss pharmaceutical company developing drugs for inflammatory diseases, has announced topline data from its CT05 phase IIa study of small molecule macrophage metabolic modulator MP1032 in COVID-19… December 8, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 6 May 2025 The future of diabetes treatment: Is a cure possible? …to multiple chronic diseases, including diabetes. Recent studies have explored interventions aimed at modulating the gut microbiota to improve glycemic control. For instance, fecal microbiota transplantation (FMT) has been investigated… May 6, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 13 Aug 2018 Orchard Therapeutics Raises €132M to Develop Gene Therapies …most advanced clinical programs, which aim to treat rare inherited metabolic and immune system diseases. The news follows Orchard’s acquisition of GSK’s entire gene therapy portfolio last year, including Strimvelis,… August 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 Apr 2020 Sofinnova Invests €20M in Three Italian Rare Disease Biotechs …treatments to tackle a range of rare genetic diseases such as inflammatory skin conditions and metabolic disorders. Genespire received €16M of the funding, though the precise amounts received by the… April 23, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2017 Two Big Pharma Players Team up to Take Over the NASH Space …compounds attack the metabolic stages of NASH and as Marco Boorsma, a partner at Forbion Partners told us in our recent NASH review: FXR has been a target of great… April 18, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 The 2024 drug approval list: Eight new treatments you should know about …the potentially life-threatening liver condition metabolic dysfunction-associated steatohepatitis (MASH), Rezdiffra received the green light from the U.S. Food and Drug Administration (FDA) to treat the disease back in March. MASH… June 27, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 2 Nov 2023 How French pharma giant Sanofi is betting big on AI …drugs for metabolic diseases, before Sanofi then in-licensed one of the candidates in 2019. As it turned out, 2022 brought with it three more major AI deals for Sanofi. These… November 2, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2017 French Biotech fails Second Phase II Trial for Cardiovascular Disease …cardiovascular and metabolic diseases. The company now presented data on its lead candidate CER-001, which was investigated in a Phase II study for the treatment of patients with post-acute coronary… March 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email